New biologic drug tested for debilitating skin blister disease
NCT ID NCT07503652
Summary
This study is observing a drug called Xeligekimab to see if it can help control moderate-to-severe palmoplantar pustulosis (PPP), a chronic skin disease that causes painful blisters and scales on the palms and soles. It will involve 10 adult patients who have not responded well to other treatments. The main goal is to see if the drug reduces symptoms and improves quality of life, while also checking for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PALMOPLANTAR PUSTULOSIS (PPP) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
First Hospital of China Medical University
RECRUITINGShenyang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.